MN-ASI-DATAMYTE
11.12.2015 11:01:06 CET | Business Wire | Press release
ASI DATAMYTE, Inc., the leader in global quality management solutions, announces today a multinational partnership with NEXTSENSE GmbH, the leader in the production of laser-based profile measurement solutions for manufacturers, worldwide. The automotive industry is evolving with more complex designs using a broader variety of materials; which is creating the need for a more comprehensive measurement solutions for ensuring accuracy, inspection thoroughness and operator repeatability. As part of this new relationship, ASI DATAMYTE will now support this market need by offering CALIPRI product line to the automotive industry.
“CALIPRI is one of the fastest-growing, scalable, non-contact measurement solutions in the market,” said Sven Tetzlaff, ASI DATAMYTE GmbH head of product and general manager. “We are confident the combination of CALIPRI and our expertise, technology and client base, creates unmatched value for automotive companies looking to produce higher quality products. We will now have a streamlined solution using one technology supporting the inline and automated measurement throughout the production process.”
“We are committed to continuing our investments and innovation in our state-of-the-art optical sensor technology that will empower the future of ASI DATAMYTE’s clients and distributors,” said Clemens Gasser, chief executive officer, NEXTSENSE GmbH. “We are looking forward to watching our partnership redefine quality measurement and data collection across the globe.”
About ASI DATAMYTE
ASI DATAMYTE Inc. provides integrated software, hardware and services for driving best-in-class quality in manufacturing. Refining its solutions for more than 40 years, ASI DATAMYTE is serving the largest, most prestigious manufacturers with localized solutions on a global basis. ASI DATAMYTE is headquartered in Plymouth, MN, with offices and support centers in more than 40 countries.
About NEXTSENSE
NEXTSENSE GmbH is a global leader in producing and distributing revolutionary solutions for profile measurement and surface inspection, called CALIPRI and SURFILES. All solutions are based on non-contact measurement technology which captures unbiased measurement data removing all outside variables based on differences between operators or environmental conditions. NEXTSENSE devices are used for gap and flush measurement of automotive bodies, wear measurement of railway wheelsets and analyzing the surfaces of rolled steel. The client list ranges from international automobile manufactures (e.g. Volkswagen, Toyota, General Motors) to well-known international enterprises in the railway, steel and technology industry such as SNCF, AcelorMittal and Miele).
View source version on businesswire.com: http://www.businesswire.com/news/home/20151211005140/en/
Contact:
ASI DATAMYTE Inc.
Mary Braunwarth
mary.braunwarth@asidatamyte.com
+1.763.553.0455
info@asidatamyte.com
www.asidatamyte.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release
Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release
The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter
Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release
Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant
Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom